Pilot study: Urine cell-free DNA with low-pass whole genome sequencing can detect and molecularly type upper tract urothelial carcinomas
We demonstrated the superiority of urine vs plasma cfDNA when LPWGS was used to identify UTUC-associated gene abnormalities. Voided urine cfDNA molecular signatures are highly concordant with matched tumor tissue on chromosomal and subchromosomal levels, emphasizing its feasibility as a noninvasive biomarker for UTUC detection and surveillance.
Authors
- Maria Tretiakova (ORCID: https://orcid.org/0000-0002-0819-9638)
- Luisa Angelica Lerma (ORCID: https://orcid.org/0000-0002-5606-4340)
- Alexander Zhu (ORCID: https://orcid.org/0000-0002-0153-9134)
- Carolyn Quinn
- Christina M. Lockwood (ORCID: https://orcid.org/0000-0001-9036-7604)
- Raymond J. Monnat (ORCID: https://orcid.org/0000-0001-7638-7393)
- Jonathan Lawrence Wright (ORCID: https://orcid.org/0000-0002-8447-8209)
Institutions
- University of Washington (US)
- University of Washington Applied Physics Laboratory (US)
Publication Details
- Journal
- American Journal of Clinical Pathology
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1093/ajcp/aqae175
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01